Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials

Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas

(2018) Maud Toulmonde et al.   JAMA Oncology

Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies

(2017) Matthew J. Reilley et al.   Journal for ImmunoTherapy of Cancer

Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma

(2016) Chan Kim et al.   BMC CANCER

Modeling Alveolar Soft Part Sarcoma Unveils Novel Mechanisms of Metastasis

(2016) Miwa Tanaka et al.   CANCER RESEARCH

PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors

(2016) Adrian M. Seifert et al.   CLINICAL CANCER RESEARCH

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

(2016) Stéphane Champiat et al.   CLINICAL CANCER RESEARCH

Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma

(2016) Georgia J. B. McCaughan et al.   Journal of Hematology & Oncology

Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype

(2016) Marie Kostine et al.   MODERN PATHOLOGY

Three-year Follow up of GMCSF/bi-shRNA furin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma

(2016) Maurizio Ghisoli et al.   MOLECULAR THERAPY

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion

(2016) Vivek Subbiah et al.   ONCOLOGY

Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials

(2016) J. Andrew Livingston et al.   Oncotarget

Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies

(2016) Vivek Subbiah et al.   Scientific Reports

Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma

(2015) M. Duvic et al.   BLOOD

Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment

(2015) Sandra P. D’Angelo et al.   HUMAN PATHOLOGY

CCR4 and its ligands: from bench to bedside

(2014) O. Yoshie et al.   INTERNATIONAL IMMUNOLOGY

Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors

(2013) S. Rusakiewicz et al.   CANCER RESEARCH

CD8+tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma

(2013) Hiroko Fujii et al.   INTERNATIONAL JOURNAL OF CANCER

Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas

(2013) Jung Ryul Kim et al.   PLoS One

Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center

(2011) Ignacio Garrido-Laguna et al.   CANCER

Phase 1 clinical trials for sarcomas: the cutting edge

(2011) Vivek Subbiah et al.   CURRENT OPINION IN ONCOLOGY

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido

(2011) Vinod P Balachandran et al.   NATURE MEDICINE

Prognostic Impact of Lymphocytes in Soft Tissue Sarcomas

(2011) Sveinung W. Sorbye et al.   PLoS One

The BATTLE Trial: Personalizing Therapy for Lung Cancer

(2011) Edward S. Kim et al.   Cancer Discovery

Mifamurtide

(2010) James E. Frampton   PEDIATRIC DRUGS